Baiotai BioBAT1806 (Tozhu monoantigen) Global Phase III clinical study has completed the first patient administration

recently, BaiotaI Biotech (Guangzhou) LimitedCompany(http:// announcedthat the company has completed its first patient administration in the global clinical study of the bio-
pharmaceutical(http://BAT1806 (Tozhu mono-injection) Global Phase III clinical studyabout BAT1806
BAT1806 is a target-to-leukin-6 receptor (IL) developed by Baiota in accordance with China's NMPA, U.SFDA(http://, EU EMA Biosimilar Sin-Related Guidelines -6R) recombinant humanized monoclonal antibody, which can be specifically bound with soluble and membrane-binding IL-6 receptors (sIL-6R and mIL-6R) and inhibits signal conduction mediated by sIL-6R or mIL-6R, BAT1806 is currently conducting a global Phase III clinical study for the treatment of rheumatoid arthritisrelated researchthis study is an international multicenter, randomized, double-blind, parallel, positive control Phase III clinical study, conducted in patients with rheumatoid arthritis (RA) to compare bat1806 with The RoActemra/Actemra, generic name: tocizumab, tocozot, immunogenicand and pharmacodynamicsthe Phase III study, which will be conducted in more than 45 research centers around the world, is scheduled to enroll more than 600 patients and is expected to be published in the second half of 2020Baota is expected to submit BAT1806 listing applications in China, the United States and Europe in 2021